{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:34:30Z","timestamp":1791588870783,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007730","name":"American Medical Systems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ejca.2023.112986","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T12:28:48Z","timestamp":1689078528000},"page":"112986","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp"],"prefix":"10.1016","volume":"191","author":[{"given":"Jessica C.","family":"Hassel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6185-4945","authenticated-orcid":false,"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7090-9584","authenticated-orcid":false,"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4340-9706","authenticated-orcid":false,"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ochsenreither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8772-4778","authenticated-orcid":false,"given":"Jens","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.112986_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070971","article-title":"Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma","volume":"11","author":"Damato","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2023.112986_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/imm.12779","article-title":"Polyfunctional response by ImmTAC (IMCgp100) redirected CD8(+) and CD4(+) T cells","volume":"152","author":"Boudousquie","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.ejca.2023.112986_bib3","unstructured":"Kimmtrak Summary of Product Characteristics. 2022."},{"key":"10.1016\/j.ejca.2023.112986_bib4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/1078-0432.CCR-22-0028","article-title":"Redirecting polyclonal T cells against cancer with soluble T cell receptors","volume":"29","author":"Berman","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.112986_bib5","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma.","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.112986_bib6","first-page":"2364","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat\u00a0Med"},{"key":"10.1016\/j.ejca.2023.112986_bib7","first-page":"9585","article-title":"Treatment with tebentafusp beyond radiographic progressive disease (PD) in metastatic uveal melanoma (mUM)","volume":"40","author":"Sullivan","year":"2022","journal-title":"J\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.112986_bib8","article-title":"Metastatic uveal melanoma: the final frontier","volume":"90","author":"Rantala","year":"2022","journal-title":"Prog\u00a0Retin\u00a0Eye Res"},{"key":"10.1016\/j.ejca.2023.112986_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/OPTH.S120530","article-title":"Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973-2012)","volume":"11","author":"Mahendraraj","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ejca.2023.112986_bib10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/eye.2016.275","article-title":"Uveal melanoma: relatively rare but deadly cancer","volume":"31","author":"Kaliki","year":"2017","journal-title":"Eye"},{"key":"10.1016\/j.ejca.2023.112986_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: treatment options and future prospects","volume":"101","author":"Carvajal","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ejca.2023.112986_bib12","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/j.ejca.2015.07.013","article-title":"Uveal melanoma UK national guidelines","volume":"51","author":"Nathan","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.112986_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ctrv.2017.08.009","article-title":"Immune checkpoint blockade for unresectable or metastatic uveal melanoma: a systematic review","volume":"60","author":"Heppt","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2023.112986_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2016.07.003","article-title":"Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma","volume":"65","author":"Kirchberger","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.112986_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2023.112986_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejca.2023.112986_bib17","first-page":"S356","article-title":"A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma","volume":"33","author":"Piulats Rodriguez","year":"2022","journal-title":"Ann\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.112986_bib18","unstructured":"RoActemra Summary of Product Characteristics. 2021."},{"key":"10.1016\/j.ejca.2023.112986_bib19","first-page":"S356","article-title":"Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma","volume":"33","author":"Schlaak","year":"2022","journal-title":"Ann\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.112986_bib20","first-page":"761","article-title":"Das uveale Melanom \u2013 standardisiertes Vorgehen in Diagnostik, Therapie und Nachsorge","volume":"238","author":"Bechrakis","year":"2021","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.ejca.2023.112986_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1590\/0104-1169.2896.2392","article-title":"Correlation between body temperature, blood pressure and plasmatic nitric oxide in septic patients","volume":"22","author":"Pereira","year":"2014","journal-title":"Rev Lat Am Enfermagem"},{"key":"10.1016\/j.ejca.2023.112986_bib22","first-page":"S829","article-title":"Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma","volume":"32","author":"Salama","year":"2021","journal-title":"Ann\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.112986_bib23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40264-018-0760-1","article-title":"Benefit-risk assessment of blinatumomab in the treatment of relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"42","author":"Stein","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.ejca.2023.112986_bib24","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1182\/blood-2018-99-117353","article-title":"A retrospective review of tocilizumab for the management of blinatumomab (a bispecific T cell engager)-induced cytokine release syndrome (CRS)","volume":"132","author":"Choudhry","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.112986_bib25","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.112986_bib26","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.2147\/OTT.S103470","article-title":"Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab","volume":"10","author":"Queudeville","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ejca.2023.112986_bib27","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.112986_bib28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2023.112986_bib29","doi-asserted-by":"crossref","first-page":"S356","DOI":"10.1016\/j.annonc.2022.07.958","article-title":"Treatment sequence with tebentafusp (tebe) and anti-PD1\/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM)","volume":"33","author":"Dimitriou","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.112986_bib30","first-page":"20","article-title":"Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study","volume":"115","author":"Mouriaux","year":"2016","journal-title":"Br\u00a0J\u00a0Cancer"},{"key":"10.1016\/j.ejca.2023.112986_bib31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00432-016-2318-x","article-title":"Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma","volume":"143","author":"Atkinson","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2023.112986_bib32","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/cancers11060845","article-title":"Uveal versus cutaneous melanoma; same origin, very distinct tumor types","volume":"11","author":"van der Kooij","year":"2019","journal-title":"Cancers ((Basel))"},{"key":"10.1016\/j.ejca.2023.112986_bib33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5802\/crbiol.63","article-title":"Cutaneous and uveal melanoma: two different cancers in therapeutic needs","volume":"344","author":"Bertolotto","year":"2021","journal-title":"C R Biol"},{"key":"10.1016\/j.ejca.2023.112986_bib34","first-page":"8","article-title":"Comprehensive analysis of cutaneous and uveal melanoma liver metastases","author":"Hoefsmit","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2023.112986_bib35","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/cncr.29727","article-title":"Uveal melanoma: from diagnosis to treatment and the science in between","volume":"122","author":"Chattopadhyay","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.112986_bib36","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/ijms22010336","article-title":"Genetics of ocular melanoma: insights into genetics, inheritance and testing","volume":"22","author":"van Poppelen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2023.112986_bib37","first-page":"334","article-title":"Frequencies of HLA-A2 alleles in five U.S. population groups: predominance of A\u221702011 and identification of HLA-A\u22170231","volume":"61","author":"Ellis","year":"2000","journal-title":"Hum\u00a0Immunol"},{"key":"10.1016\/j.ejca.2023.112986_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101408","article-title":"Tebentafusp in first-line melanoma trials: an outperforming outlier","volume":"20","author":"Olivier","year":"2022","journal-title":"Transl Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:43:06Z","timestamp":1760733786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923003386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":38,"alternative-id":["S0959804923003386"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.112986","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.112986","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"112986"}}